These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 38114452)

  • 1. Broadening and strengthening the health providers caring for patients with chronic hepatitis C may improve continuity of care.
    Clark PJ; Valery PC; Strasser SI; Weltman M; Thompson A; Levy MT; Leggett B; Zekry A; Rong J; Sinclair M; George J; Bollipo S; McGarity B; Sievert W; MacQuillan G; Tse E; Nicoll A; Wade A; Cheng W; Roberts SK
    J Gastroenterol Hepatol; 2024 Mar; 39(3):568-575. PubMed ID: 38114452
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatitis C treatment outcomes for Australian First Nations Peoples: equivalent SVR rate but higher rates of loss to follow-up.
    Clark PJ; Valery PC; Ward J; Strasser SI; Weltman M; Thompson A; Levy MT; Leggett B; Zekry A; Rong J; Angus P; George J; Bollipo S; McGarity B; Sievert W; Macquillan G; Tse E; Nicoll A; Wade A; Chu G; Harding D; Cheng W; Farrell G; Roberts SK
    BMC Gastroenterol; 2022 Jul; 22(1):339. PubMed ID: 35820850
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Liver Disease and Poor Adherence Limit Hepatitis C Cure: A Real-World Australian Treatment Cohort.
    Clark PJ; Valery PC; Strasser SI; Weltman M; Thompson AJ; Levy M; Leggett B; Zekry A; Rong J; Angus P; George J; Bollipo S; McGarity B; Sievert W; Macquillan G; Tse E; Nicoll A; Wade A; Chu G; Harding D; Cheng W; Farrell G; Roberts SK
    Dig Dis Sci; 2023 Jan; 68(1):291-303. PubMed ID: 35552941
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Direct-acting antiviral treatment of chronic HCV-infected patients on opioid substitution therapy: Still a concern in clinical practice?
    Christensen S; Buggisch P; Mauss S; Böker KHW; Schott E; Klinker H; Zimmermann T; Weber B; Reimer J; Serfert Y; Wedemeyer H
    Addiction; 2018 May; 113(5):868-882. PubMed ID: 29359361
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Delivering direct acting antiviral therapy for hepatitis C to highly marginalised and current drug injecting populations in a targeted primary health care setting.
    Read P; Lothian R; Chronister K; Gilliver R; Kearley J; Dore GJ; van Beek I
    Int J Drug Policy; 2017 Sep; 47():209-215. PubMed ID: 28587943
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness of direct-acting antiviral therapy among Aboriginal and Torres Strait Islander peoples with HCV infection in Australia: A national real-world cohort (REACH-C).
    Hudson-Buhagiar J; Carson J; Monaghan S; Collie P; Nelson R; Van Gessel H; Read P; Hanson J; Monaghan R; Matthews G; Dore GJ; Martinello M;
    J Viral Hepat; 2023 May; 30(5):386-396. PubMed ID: 36651627
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factors associated with lost to follow-up after hepatitis C treatment delivered by primary care teams in an inner-city multi-site program, Vancouver, Canada.
    Nouch S; Gallagher L; Erickson M; Elbaharia R; Zhang W; Wang L; Bacani N; Kason D; Kleban H; Knebel L; Hall D; Barrios R; Hull M
    Int J Drug Policy; 2018 Sep; 59():76-84. PubMed ID: 30048877
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sustained Virologic Response and Costs Associated with Direct-Acting Antivirals for Chronic Hepatitis C Infection in Oklahoma Medicaid.
    Pham TT; Keast SL; Farmer KC; Thompson DM; Rathbun RC; Nesser NJ; Holderread BP; Skrepnek GH
    J Manag Care Spec Pharm; 2018 Jul; 24(7):664-676. PubMed ID: 29952711
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical outcomes following DAA therapy in patients with HCV-related cirrhosis depend on disease severity.
    Krassenburg LAP; Maan R; Ramji A; Manns MP; Cornberg M; Wedemeyer H; de Knegt RJ; Hansen BE; Janssen HLA; de Man RA; Feld JJ; van der Meer AJ
    J Hepatol; 2021 May; 74(5):1053-1063. PubMed ID: 33242501
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Direct-acting antiviral therapy for hepatitis C: The initial experience of the University of Cape Town/Groote Schuur Hospital Liver Clinic, South Africa.
    Sonderup MW; Gogela N; Nordien R; Smuts H; Korsman S; Hardie D; Spearman CW
    S Afr Med J; 2020 Jan; 110(2):112-117. PubMed ID: 32657680
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alcohol Use and Sustained Virologic Response to Hepatitis C Virus Direct-Acting Antiviral Therapy.
    Cartwright EJ; Pierret C; Minassian C; Esserman DA; Tate JP; Goetz MB; Bhattacharya D; Fiellin DA; Justice AC; Lo Re V; Rentsch CT
    JAMA Netw Open; 2023 Sep; 6(9):e2335715. PubMed ID: 37751206
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incidence of Hepatocellular Carcinoma in Patients With HCV-Associated Cirrhosis Treated With Direct-Acting Antiviral Agents.
    Calvaruso V; Cabibbo G; Cacciola I; Petta S; Madonia S; Bellia A; Tinè F; Distefano M; Licata A; Giannitrapani L; Prestileo T; Mazzola G; Di Rosolini MA; Larocca L; Bertino G; Digiacomo A; Benanti F; Guarneri L; Averna A; Iacobello C; Magro A; Scalisi I; Cartabellotta F; Savalli F; Barbara M; Davì A; Russello M; Scifo G; Squadrito G; Cammà C; Raimondo G; Craxì A; Di Marco V;
    Gastroenterology; 2018 Aug; 155(2):411-421.e4. PubMed ID: 29655836
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reverse inflammaging: Long-term effects of HCV cure on biological age.
    Oltmanns C; Liu Z; Mischke J; Tauwaldt J; Mekonnen YA; Urbanek-Quaing M; Debarry J; Maasoumy B; Wedemeyer H; Kraft ARM; Xu CJ; Cornberg M
    J Hepatol; 2023 Jan; 78(1):90-98. PubMed ID: 36152762
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High Effectiveness of Broad Access Direct-Acting Antiviral Therapy for Hepatitis C in an Australian Real-World Cohort: The REACH-C Study.
    Yee J; Carson JM; Hajarizadeh B; Hanson J; O'Beirne J; Iser D; Read P; Balcomb A; Doyle JS; Davies J; Martinello M; Marks P; Dore GJ; Matthews GV;
    Hepatol Commun; 2022 Mar; 6(3):496-512. PubMed ID: 34729957
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment-failure to direct antiviral HCV regimens in real world: frequency, patient characteristics and rescue therapy - data from the German hepatitis C registry (DHC-R).
    Schmitt A; Günther R; Mauss S; Boeker KHW; Buggisch P; Hillenbrand H; John C; Klinker H; Pathil A; Simon KG; Serfert Y; Niederau C; Vermehren J; Wedemeyer H; Sarrazin C
    Z Gastroenterol; 2020 Apr; 58(4):341-351. PubMed ID: 32040979
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patient-reported symptoms during and after direct-acting antiviral therapies for chronic hepatitis C: The PROP UP study.
    Evon DM; Sarkar S; Amador J; Lok AS; Sterling RK; Stewart PW; Reeve BB; Serper M; Reau N; Rajender Reddy K; Di Bisceglie AM; Nelson DR; Golin CE; Lim JK; Fried MW
    J Hepatol; 2019 Sep; 71(3):486-497. PubMed ID: 31096006
    [TBL] [Abstract][Full Text] [Related]  

  • 17. All-oral Direct-acting Antiviral Regimens in HIV/Hepatitis C Virus-coinfected Patients With Cirrhosis Are Efficient and Safe: Real-life Results From the Prospective ANRS CO13-HEPAVIH Cohort.
    Sogni P; Gilbert C; Lacombe K; Piroth L; Rosenthal E; Miailhes P; Gervais A; Esterle L; Chas J; Poizot-Martin I; Dominguez S; Simon A; Morlat P; Neau D; Zucman D; Bouchaud O; Lascoux-Combe C; Bani-Sadr F; Alric L; Goujard C; Vittecoq D; Billaud E; Aumaître H; Boué F; Valantin MA; Dabis F; Salmon D; Wittkop L
    Clin Infect Dis; 2016 Sep; 63(6):763-770. PubMed ID: 27317796
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatitis C treatment uptake and response among human immunodeficiency virus/hepatitis C virus-coinfected patients in a large integrated healthcare system.
    Lam JO; Hurley LB; Chamberland S; Champsi JH; Gittleman LC; Korn DG; Lai JB; Quesenberry CP; Ready J; Saxena V; Seo SI; Witt DJ; Silverberg MJ; Marcus JL
    Int J STD AIDS; 2019 Jun; 30(7):689-695. PubMed ID: 31046611
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Health care utilization and costs associated with direct-acting antivirals for patients with substance use disorders and chronic hepatitis C.
    Jiang X; Vouri SM; Diaby V; Lo-Ciganic W; Parker R; Park H
    J Manag Care Spec Pharm; 2021 Oct; 27(10):1388-1402. PubMed ID: 34595949
    [No Abstract]   [Full Text] [Related]  

  • 20. Hepatocellular carcinoma decreases the chance of successful hepatitis C virus therapy with direct-acting antivirals.
    Prenner SB; VanWagner LB; Flamm SL; Salem R; Lewandowski RJ; Kulik L
    J Hepatol; 2017 Jun; 66(6):1173-1181. PubMed ID: 28161470
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.